Diarrhea News and Research

Latest Diarrhea News and Research

Soy products meet nutritional needs of people with lactose intolerance

Today, nutrition experts and physicians who participated in the NIH Consensus Development Conference on Lactose Intolerance and Health released an important report that concluded individuals who ingest inadequate amounts of calcium and vitamin D because of real or perceived lactose intolerance need dietary advice to ensure appropriate intake of missing nutrients.

25 Feb 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Senate Committee report addresses U.S. government response to Haiti

A Senate Foreign Relations Committee report, written by two Senate staffers, who just returned from Haiti where they assessed relief efforts, draws attention to "immediate shelter and sanitation concerns" and voices "concern about the coordination of Washington's U.S. government response to Haiti," Politico's Laura Rozen writes on her blog. A link to the text of the report appears on Politico's Web site.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Higher rates of infant and maternal mortality have lead to a decline of life expectancy in North Korea over the past 15 years, census figures, which were obtained with help form the U.N. Population Fund, said on Monday, Agence France-Presse reports (2/22).

23 Feb 2010

Haitian President says up to 300,000 people could have died in quake

The major earthquake in January in Haiti could have killed as many as 300,000 people, an estimate that includes bodies buried in the rubble, Haitian President Rene Preval said on Sunday at a meeting of Latin American and Caribbean leaders in Mexico, Reuters reports.

23 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

A new Cochrane review did not find clear evidence that taking zinc supplements reduces the occurrence of middle ear infections or otitis media in healthy children.

18 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.

16 Feb 2010

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

A set of proteins found in our intestines can recognize and kill bacteria that have human blood type molecules on their surfaces, scientists at Emory University School of Medicine have discovered.

15 Feb 2010

Researchers describe the structure of ToxT that controls virulent nature of Vibrio cholerae

In a new study, Dartmouth researchers describe the structure of a protein called ToxT that controls the virulent nature of Vibrio cholerae, the bacteria that causes cholera. Buried within ToxT, the researchers were surprised to find a fatty acid that appears to inhibit ToxT, which prevents the bacteria from causing cholera.

14 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Soy products meet nutritional needs of people with lactose intolerance

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Senate Committee report addresses U.S. government response to Haiti

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Haitian President says up to 300,000 people could have died in quake

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Researchers describe the structure of ToxT that controls virulent nature of Vibrio cholerae

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in